International experts in the field of diabetes and diabetes technology met in Madrid, Spain, for the 9th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts, thus facilitating new collaborations and research projects to improve the lives of people with diabetes. The 2016 meeting comprised a comprehensive scientific program, parallel interactive workshops, and two keynote lectures.
Get full access to this article
View all access options for this article.
References
1.
MenkeA, CasagrandeS, GeissL, CowieCC: Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA, 2015; 314:1021–1029.
2.
WeinstockRS, DuBoseSN, BergenstalRM, et al.: Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. Diabetes Care, 2016; 39:603–610.
3.
SussmanM, SierraJA, GargS, et al.: Economic impact of hypoglycemia among insulin-treated patients with diabetes. J Med EconJun132016:1–23.
4.
BaileyTS, GrunbergerG, BodeBW, et al.: American Association of Clinical Endocrinologists and American College of Endocrinology 2016. Outpatient glucose monitoring consensus statement. Endocr Pract, 2016; 22:231–261.
5.
BergenstalRM, AhmannAJ, BaileyT, et al.: Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile (AGP). Diabetes Technol Ther, 2013; 15:198–211.
6.
PozzilliP, BattelinoT, DanneT, et al.: Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev, 2016; 32:21–39.
7.
DanneT, BangstadHJ, DeebL, et al.; ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes, 2014; 15(Suppl 20):115–134.
8.
KordonouriO, PankowskaE, RamiB, et al.: Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia, 2010; 53:2487–2495.
9.
DanneT, AschemeierB, PerfettiR; SWEET Group. SWEET—where are we heading with international type 1 diabetes registries?. Pediatr Diabetes, 2012; 13(Suppl 16):1–4.
10.
PerantieDC, WuJ, KollerJM, et al.: Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care, 2007; 30:2331–2337.
11.
PerantieDC, LimA, WuJ, et al.: Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes, 2008; 9:87–95.
12.
MaurasN, MazaikaP, BuckinghamB, et al.: Longitudinal assessment of neuroanatomical and cognitive differences in young children with type 1 diabetes: association with hyperglycemia. Diabetes, 2015; 64:1770–1779.
13.
LipskaKJ, RossJS, MiaoY, et al.: Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med, 2015; 175:356–362.
14.
PolonskyWH, HajosTR, DainMP, SnoekFJ: Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin, 2011; 27:1169–1174.
15.
HarrisSB, KaporJ, LankCN, et al.: Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician, 2010; 56:e418–e424.
16.
KhuntiK, NikolajsenA, ThorstedBL, et al.: Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab, 2016; 18:401–409.
17.
BaxterM, HudsonR, MahonJ, et al.: Estimating the impact of better management of glycaemic control in adults with type 1 and type 2 diabetes on the number of clinical complications, and the associated financial benefit. Diabet Med, 2016. DOI: 10.1111/dme.13062.
18.
McQueenRB, BretonMD, OttM, et al.: Economic value of improved accuracy for self-monitoring of blood glucose devices for type 1 diabetes in Canada. J Diabetes Sci Technol, 2016; 10:366–377.
19.
PuckreinG, Nunlee-BlandG, ZangenehF, et al.: Impact of CMS competitive bidding program on Medicare beneficiary safety and access to diabetes testing supplies: a retrospective, longitudinal analysis. Diabetes Care, 2016; 39:563–571.
20.
PetersonA: Improving type 1 diabetes management with mobile tools: a systematic review. J Diabetes Sci Technol, 2014; 8:859–864.
21.
PolonskyWH, FisherL, SchikmanCH, et al.: Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care, 2011; 34:262–267.
22.
HinnenDA, BuskirkA, LydenM, et al.: Use of diabetes data management software reports by health care providers, patients with diabetes, and caregivers improves accuracy and efficiency of data analysis and interpretation compared with traditional logbook data: first results of the Accu-Chek Connect Reports Utility and Efficiency Study (ACCRUES). J Diabetes Sci Technol, 2015; 9:293–301.
23.
BrazgRL, KlaffLJ, SussmanAM: New generation blood glucose monitoring system exceeds international accuracy standards. J Diabetes Sci TechnolJune52016. DOI: 10.1177/1932296816652902.
24.
AjjanRA, AbougilaK, BellaryS, et al.: Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes. Diab Vasc Dis Res, 2016. DOI: 10.1177/1479164115624680.
25.
ComellasMJ, CorcoyR, Fernández-GarciaD, et al.: Evaluación de un nuevo modulo de detección automática de patrones glucémicos. Endocrinol Nutr, 2016; 63(Espec Cong):108.
26.
MillerKM, BeckRW, BergenstalRM, et al.: Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care, 2013; 36:2009–2014.
27.
AdriaanseMA, De RidderTD, VoornemanI: Improving diabetes self-management by mental contrasting. Psychol Health, 2013; 28:1–12.
28.
OettingenG: Rethinking Positive Thinking: Inside the New Science of Motivation. New York, NY: Penguin Random House, 2014.
29.
HickeyMS, PoriesWJ, MacDonaldKGJr., et al.: A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut?. Ann Surg, 1998; 227:637–643; discussion 643–644.
30.
SchauerPR, BurgueraB, IkramuddinS, et al.: Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg, 2003; 238:467–484; discussion 84–85.
31.
CourcoulasAP, ChristianNJ, BelleSH, et al.: Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA, 2013; 310:2416–2425.
32.
PoriesWJ, SwansonMS, MacDonaldKG, et al.: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg, 1995; 222:339–350; discussion 350–352.
33.
SchauerPR, MingroneG, IkramuddinS, WolfeB: Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care, 2016; 39:902–911.
34.
SchauerPR, KashyapSR, WolskiK, et al.: Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med, 2012; 366:1567–1576.
35.
IkramuddinS, KornerJ, LeeWJ, et al.: Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA, 2013; 309:2240–2249.
36.
MingroneG, PanunziS, De GaetanoA, et al.: Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med, 2012; 366:1577–1585.
37.
KoehestanieP, de JongeC, BerendsFJ, et al.: The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg, 2014; 260:984–992.
38.
ArterburnDE, OlsenMK, SmithVA, et al.: Association between bariatric surgery and long-term survival. JAMA. 2015; 313:62–70.
39.
ChristouNV, SampalisJS, LibermanM, et al.: Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg, 2004; 240:416–423; discussion 423–424.
40.
BorotS, FrancS, CristanteJ, et al.: Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies. J Diabetes Sci Technol, 2014; 8:1133–1141.
41.
KameckeU, FreckmannG, HeinemannL, et al.: Occlusion alarm of insulin pumps: is detection fast enough for children?39th International Conference on Advanced Technologies & Treatments for Diabetes, Milan, Italy, February 3–6, 2016. ATTD-0369.
42.
ZisserH, BretonM, DassauE, et al.: Novel methodology to determine the accuracy of the OmniPod insulin pump: a key component of the artificial pancreas system. J Diabetes Sci Technol, 2011; 5:1509–1518.
43.
SteineckI, CederholmJ, EliassonB, et al.: Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ, 2015; 350:h3234.
44.
RenardE, Schaepelynck-BelicarP, EVADIAC Group: Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab, 2007; 33:158–166.
45.
LieblA, HoogmaR, RenardE, et al.: A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab, 2009; 11:1001–1008.
46.
SchmidtMI, Hadji-GeorgopoulosA, RendellM, et al.: The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care, 1981; 4:579–585.
47.
BouchonvilleMF, JaghabJJ, Duran-ValdezE, et al.: The effectiveness and risks of programming an insulin pump to counteract the dawn phenomenon in type 1 diabetes. Endocr Pract, 2014; 20:1290–1296.
48.
PerrielloG, De FeoP, TorloneE, et al.: The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia, 1991; 34:21–28.
49.
CampbellPJ, BolliGB, CryerPE, GerichJE: Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med, 1985; 312:1473–1479.
50.
PhillipM, BattelinoT, AtlasE, et al.: Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med, 2013; 368:824–833.
51.
KowalskiAJ: Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther, 2009; 11(Suppl 1):S113–S119.
52.
BergenstalRM, KlonoffDC, GargSK, et al.: Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med, 2013; 369:224–232.
53.
BuckinghamBA, RaghinaruD, CameronF, et al.: Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. Diabetes Care, 2015; 38:1197–1204.
54.
ZeladaH, Bernabe-OrtizA, ManriqueH: Inhospital mortality in patients with type 2 diabetes mellitus: a prospective cohort study in Lima, Peru. J Diabetes Res, 2016; 2016:7287215.
55.
HuFB: Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care, 2011; 34:1249–1257.
56.
MontmayeurJ-P, le CoutreJ: Fat Detection: Taste, Texture, and Post Ingestive Effects. Boca Raton, Florida: CRC Press/Taylor & Francis, 2010.
57.
CoolingJ, BlundellJ: Are high-fat and low-fat consumers distinct phenotypes? Differences in the subjective and behavioural response to energy and nutrient challenges. Eur J Clin Nutr, 1998; 52:193–201.
58.
HattersleyAT, AshcroftFM: Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes, 2005; 54:2503–2513.
59.
SteeleAM, ShieldsBM, WensleyKJ, et al.: Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA, 2014; 311:279–286.
